iShares U.S. Medical Devices ETF (IHI)
- Previous Close
54.70 - Open
54.95 - Bid 55.51 x 900
- Ask 55.52 x 1000
- Day's Range
54.83 - 55.56 - 52 Week Range
43.96 - 59.14 - Volume
416,590 - Avg. Volume
1,193,150 - Net Assets 5.76B
- NAV 54.70
- PE Ratio (TTM) 35.43
- Yield 0.51%
- YTD Daily Total Return 1.41%
- Beta (5Y Monthly) 1.05
- Expense Ratio (net) 0.40%
The fund will invest at least 80% of its assets in the component securities of the index and in investments that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents, as well as in securities not included in the index, but which BFA believes will help the fund track the index. The fund is non-diversified.
iShares
Fund Family
Health
Fund Category
5.76B
Net Assets
2006-05-01
Inception Date
Performance Overview: IHI
Trailing returns as of 4/22/2024. Category is Health.
People Also Watch
Holdings: IHI
Top 10 Holdings (71.26% of Total Assets)
Sector Weightings
Recent News: IHI
Research Reports: IHI
Analyst Report: ASML Holding NV
Netherlands-based ASML Holdings N.V. provides advanced semiconductor capital equipment solutions. ASML manufactures ultraviolet lithography systems critical to the production of integrated circuits. The company, based in Europe's top technology hub near Eindhoven, has operations in Europe, the Americas, and Asia, and employs 33,000 people. The company supplies both primary semiconductor companies such as Intel and Samsung as well as merchant foundry companies such as Taiwan Semiconductor. Together with its partners, ASML is driving the development of more affordable, more powerful, and more energy-efficient chips and devices.
RatingPrice TargetMarket Update: MAN, ASML
U.S. stocks rose on Monday morning following last week's selloff. On the economic calendar this week are flash PMI readings for April on Tuesday, durable goods orders on Wednesday, U.S. 1Q GDP and pending home sales on Thursday, and consumer sentiment on Friday. Tesla shares are down ahead of its quarterly earnings tomorrow on news that the company cut prices by up to $2000 on several of its vehicles. The Dow was up 0.4%, the S&P 500 rose 0.5% and the Nasdaq gained 0.6%. Crude oil is trading above $83 per barrel and gold fell $64 to $2349 per ounce.
Analyst Report: ASML Holding N.V.
ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML’s main clients are TSMC, Samsung, and Intel.
RatingPrice TargetAnalyst Report: Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
RatingPrice Target